PP_1170x120_10-25-21

Impel NeuroPharma

Impel NeuroPharma Announces U.S. FDA Approval of TRUDHESA

Impel NeuroPharma Announces U.S. FDA Approval of TRUDHESA

SEATTLE — Impel NeuroPharma recently announced that the U.S. Food and Drug Administration (FDA) approved TRUDHESA (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) for the acute treatment of migraine with or without aura in adults. TRUDHESA was previously known as INP104. Using Impel’s proprietary Precision Olfactory Delivery (POD) technology, TRUDHESA gently delivers dihydroergotamine mesylate

Adheris Health